首页> 中文期刊> 《检验医学与临床》 >胸腺肽联合抗菌药物对老年慢性阻塞性肺疾病急性加重期的治疗效果

胸腺肽联合抗菌药物对老年慢性阻塞性肺疾病急性加重期的治疗效果

         

摘要

Objective To investigate the effect of thymosin combined with antibacterial drugs in treating elder ‐ly patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) .Methods The clinical data in 60 elderly cases of AECOPD admitted to our hospital from January 2013 to September 2014 were statistically ana‐lyzed .Results FEV1 and FEV1% in the study group were significantly higher than those in the control group with statistical difference between them (P< 0 .05) ,the clinical symptoms and quality of life scores in the study group were significantly lower than those in the control group with statistical difference between them ( P < 0 .05) ,the total treatment effective rate in the study group was 96 .7% (29/30) ,which was significantly higher than 66 .7% (20/30) in the control group ,the difference was statistically significant (P< 0 .05) .Conclusion Thymosin combined with an‐tibacterial drugs has significant effect in the treatment of elderly AECOPD and is worthy of promotion .%目的:探讨胸腺肽联合抗菌药物对老年慢性阻塞性肺疾病急性加重期(AECOPD)的治疗效果。方法统计分析该院2013年1月至2014年9月收治的60例老年 AECOPD 患者的临床资料。结果研究组患者的1 s用力呼气量(FEV1)和 FEV1%均明显高于对照组,差异有统计学意义(P<0.05);临床症状和生活质量评分均明显低于对照组,差异有统计学意义(P<0.05);治疗的总有效率96.7%(29/30)明显高于对照组66.7%(20/30),差异有统计学意义(P<0.05)。结论胸腺肽联合抗菌药物对老年 AECOPD 的治疗效果明显,值得推广。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号